
Tatva Chintan Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
No
Capex
Yes
1 of 4 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- PTC segment: Organic volume growth of 10-15% per year historically; 2023 may see no volume growth due to sharp product price drops; topline degrowth expected in 2023; business stable with secured large MNC customers for 2024.
- PASC and SDA segments: Expected to drive future growth with commercialization starting August 2024; incremental revenue of Rs. 200 crores from PASC and Rs. 80-100 crores from SDA over next 3 years.
- Overall growth guidance: At least 70% revenue growth anticipated in FY25 driven by volume growth and new products; value erosion due to lower product pricing considered in forecasts.
- Capacity Utilization: Full utilization expected from July-August 2024; new CAPEX of about Rs. 70 crores underway to expand capacity.
- Longer-term: Growth supported by sustained export demand (~70% of revenue from exports); SDA segment demand to benefit post-2027 with BS-7 emission norms implementation.
See what Tatva Chintan management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Tatva Chintan management said on order book — free account, 30 seconds.
Capex plans
Yes- The company announced a capital expenditure (CAPEX) of Rs. 70 crore, expected to be commercialized by October 2024.
- This CAPEX is for an add-on facility at the Dahej site, including 150 KL reactors and a separate distillation plant, aiming to support commercialization of new products in the PASC (Pharma and Agro intermediates) segment.
- The Rs. 70 crore investment is to capture growth opportunities and avoid delivery mismatches, expected to generate incremental revenue of Rs. 95-100 crore.
- The company also received environmental clearance for a greenfield project at Jolva, Dahej, with construction planned to start in 2025.
- Further CAPEX was about Rs. 250 crore from IPO proceeds, leading to asset turn improvements and capacity expansion across PTC, SDA, and PASC segments.
- Additional continuous flow reactors are being added at the lab and pilot scales as part of ongoing development projects.
Track Tatva Chintan — get its next earnings analysis in your feed
How does Tatva Chintan rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Tatva Chintan rank in Chemicals & Petrochemicals?
Compare Tatva Chintan against every Chemicals & Petrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Tatva Chintan's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…